Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837213 · ClinicalTrials.gov registry record · Phase 4
Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne
A Phase 4 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT00837213: Completed Phase 4 study, sponsored by Stiefel, a GSK Company.
NCT00837213 is a Phase 4 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 33 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00837213, a Phase 4 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin vs. Benzoyl peroxide used in combination with clindamycin and doxycycline in the treatment of moderate acne
Primary Outcome
Percent change from baseline to week 16 in inflammatory acne lesions (pustules/papules)(chest and back)
Interventions
- DRUG Benzoyl peroxide with clindamycin
- DRUG Benzoyl peroxide with clindamycin and doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
What the finished NCT00837213 record still lists
NCT00837213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Benzoyl peroxide with clindamycin is the first listed.
NCT00837213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00837213 about?
NCT00837213 is a clinical study titled "Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne". To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin vs. Benzoyl peroxide used in combination with clindamycin and doxycycline in the treatment of moderate acne
What is the current status of trial NCT00837213?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2007-08. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00837213?
The interventions under investigation include: Benzoyl peroxide with clindamycin (DRUG), Benzoyl peroxide with clindamycin and doxycycline (DRUG).
Who is sponsoring clinical trial NCT00837213?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00837213's enrollment target sits among peer trials
33 1528th of 2000 higher than 467 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia